Risperidone Transdermal Patch Matrix for Stable 14-Day Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing transdermal administration systems for risperidone struggle to deliver the drug continuously at a therapeutically effective amount for 24 hours to 14 days without causing skin irritation or adhesion issues, and there is a need for a system that can maintain a constant rate of drug delivery to avoid peak levels and side effects.
Innovation Solution
A matrix-type transdermal administration system using lauryl lactate and long-chain fatty alcohols as skin penetration enhancers, combined with micronized risperidone crystal form A, to achieve sustained and controlled drug release at a constant rate for up to 14 days, with adjustments in the matrix layer components to enhance skin flux and adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If transdermal patch preparations are designed for continuous drug delivery over extended periods (7 days or more), then patient compliance and convenience are improved, but skin irritation, adhesion issues, and drug delivery stability deteriorate
Solution Approach 1:
The patent modifies the chemical composition parameters of the adhesive layer by incorporating specific penetration enhancers (oleic acid, isopropyl myristate, propylene glycol) in optimized concentrations. These parameter changes enable the adhesive to maintain effective skin bonding over extended periods while simultaneously enhancing drug permeation and reducing skin irritation, thus resolving the contradiction between duration and harmful effects.
Solution Approach 2:
The patent employs a composite adhesive system combining multiple components: base adhesive polymers, penetration enhancers, plasticizers, and stabilizers. This composite material approach creates synergistic effects where each component contributes specific properties - the base adhesive provides bonding, penetration enhancers facilitate drug delivery and reduce irritation, and plasticizers maintain flexibility. The composite structure enables the patch to function effectively for 7+ days without skin irritation or adhesion failure.
2Quantity of substance
If high doses of risperidone are delivered transdermally to achieve therapeutic blood concentrations, then treatment effectiveness is improved, but risk of side effects and skin tolerance issues increases
Solution Approach 1:
The patent designs the transdermal patch to provide continuous, low-rate delivery of risperidone over an extended period (7-14 days) rather than intermittent high-dose delivery. The controlled release mechanism maintains steady blood concentrations within the therapeutic window, avoiding peak-trough fluctuations. This continuous action delivers the required total quantity of drug while preventing side effects associated with high peak concentrations and maintaining skin tolerance throughout the wear period.
Solution Approach 2:
The patent introduces penetration enhancers (oleic acid, isopropyl myristate, propylene glycol) as intermediary substances that facilitate drug delivery through the skin. These intermediaries increase skin permeability, allowing higher total doses of risperidone to be delivered transdermally without increasing the instantaneous flux that would cause skin irritation or systemic side effects. The intermediaries mediate between the drug and skin, enabling effective dosing while maintaining skin tolerance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system ensures continuous delivery of risperidone at a therapeutically effective blood concentration, improving patient compliance and reducing side effects by maintaining a stable drug level, while being well-tolerated by the skin.
Implementation Method 1
The present invention relates to a matrix-type risperidone transdermal administration system which comprises a backing layer, a matrix layer, and a release liner layer, wherein the matrix layer contains risperidone dispersed in the matrix layer in crystalline and non-crystalline, a skin penetration enhancer and a pressure-sensitive adhesive
Implementation Method 2
matrix-type patch formulations are those in which the drug is dissolved or dispersed in a polymeric matrix layer
Data Source
AI summary
The present invention relates to a risperidone transdermal administration system. More specifically, the present invention relates to a transdermal administration system for continuously delivering risperidone or a pharmaceutically acceptable salt thereof at a therapeutically effective amount of blood drug concentration within 24 hours to 14 days, and a preparation method therefor and a use thereof.